Form 4: Hologic Merger Completes, Executive Ownership Changes

Hologic, Inc. has completed its merger, resulting in changes to executive beneficial ownership of common stock and stock options.

Summary

• This filing reports changes in beneficial ownership for Wayde D. McMillan, a Director at Hologic Inc. (HOLX).
• The changes are a result of the completion of a merger between Hologic, Inc. and Hopper Parent Inc. (through its subsidiary Hopper Merger Sub Inc.) on April 7, 2026.
• As of the merger's effective time, each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• Time-vesting restricted stock unit awards held by Mr. McMillan were also converted into the right to receive the merger consideration.
• Outstanding stock options were cancelled and converted into cash payments and/or CVRs, depending on their exercise price relative to the merger consideration.
• Following the merger, Mr. McMillan no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on the completion of a merger and the resulting changes in beneficial ownership, rather than new operational or financial performance.

Positives

• The merger has been successfully completed, providing cash and potential additional value (CVRs) to shareholders.
• The transaction offers a clear exit for shareholders at a specified cash price per share.

Negatives

• The reporting person, Wayde D. McMillan, no longer holds any direct or indirect beneficial ownership of Hologic common stock.
• The value of the CVRs is contingent and not guaranteed, introducing uncertainty for a portion of the potential payout.

Risks

• The value of the contingent value rights (CVRs) is dependent on future events and may not be fully realized.
• The filing indicates that some stock options with exercise prices at or above the cash consideration were cancelled for no value, representing a loss for those option holders.

Future Outlook

The future outlook for the reporting person is no longer tied to Hologic's stock performance as beneficial ownership has ceased. The outlook for former shareholders depends on the payout of the contingent value rights.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the completion of a significant M&A event for Hologic, Inc., a company operating in the medical technology sector. Such filings are standard following the acquisition of a public company, detailing the transition of ownership and equity awards for key personnel.

Stakeholder Impact

• Shareholders: Received $76.00 per share in cash and a contingent right to up to $3.00 per share, effectively concluding their direct equity interest in Hologic.
• Employees (including reporting person): Restricted stock units and stock options were converted into cash and/or CVRs, impacting their compensation and equity holdings.
• Creditors: The merger structure implies that Hologic's obligations to creditors will be assumed by the acquiring entity or remain with the surviving subsidiary.

Next Steps

• Shareholders will await potential payouts from the contingent value rights (CVRs).

Key Dates

Keywords

Hologic Inc, HOLX, Form 4, Merger, Beneficial Ownership, Stock Options, Restricted Stock Units, Contingent Value Rights, SEC Filing, Executive Compensation